Design and synthesis of Leukotriene A4 hydrolase inhibitors to alleviate idiopathic pulmonary fibrosis and acute lung injury.

European Journal of Medicinal Chemistry
Xiaohe LiCheng Yang

Abstract

Idiopathic pulmonary fibrosis (IPF) and acute lung injury (ALI) are considered two severe public health issues, attributed to malfunctions of neutrophils. They can cause chronic inflammation and have association with subsequent tissue damages. There have been rare drugs applying to the efficient treatment in clinical practice. Existing research revealed that Leukotriene B4 (LTB4) is the critical endogenous molecule to induce neutrophil inflammatory response. LTB4 blocking biosynthesis is the potential strategy treating IPF and ALI. In the present study, 45 hydroxamic acid derivatives were produced, and compound 26 was screened out as a highly selective Lead compound of Leukotriene A4 Hydrolase (LTA4H), i.e., an enzyme critical to the biosynthesis of LTB4. This compound is capable of relieving neutrophilic inflammation in an IPF mouse model at early stage, as well as mitigating LPS-induced acute lung injury via a mechanism of LTB4 blocking biosynthesis in vivo. Whether this compound acts as the potential lead compound for the treatment of IPF and ALI requires further verification.

References

Jul 1, 1989·The Journal of Allergy and Clinical Immunology·A J WardlawA B Kay
Apr 15, 1996·The Journal of Clinical Investigation·J WilbornM Peters-Golden
Feb 15, 2001·Nature Structural Biology·M M ThunnissenJ Z Haeggström
Jan 16, 2002·American Journal of Respiratory and Critical Care Medicine·Marc Peters-GoldenBethany B Moore
Jul 16, 2004·The Journal of Clinical Investigation·Dianhua JiangPaul W Noble
Sep 2, 2004·The Journal of Biological Chemistry·Jesper Z Haeggström
Nov 18, 2005·Cytokine & Growth Factor Reviews·Anita B RobertsKathleen C Flanders
Feb 25, 2006·Nature Reviews. Immunology·Carl Nathan
May 2, 2006·Thorax·R O'DonnellR Djukanovic
Mar 21, 2007·The Journal of Pharmacology and Experimental Therapeutics·Navin L RaoAnne M Fourie
Oct 27, 2007·Antioxidants & Redox Signaling·Benjamin D BringardnerClay B Marsh
May 23, 2009·The European Respiratory Journal·T IzumoA Nagai
Sep 4, 2010·Science·Robert J SnelgroveJ Edwin Blalock
Nov 4, 2010·Molecular Medicine·Jochen Grommes, Oliver Soehnlein
Feb 12, 2011·Archivum Immunologiae Et Therapiae Experimentalis·Elaine HayesEmer P Reeves
May 6, 2011·Journal of Medicinal Chemistry·Zheng ChenLuhua Lai
Nov 8, 2011·Journal of Leukocyte Biology·Christian D Sadik, Andrew D Luster
Jan 10, 2012·Annual Review of Immunology·Borko AmulicArturo Zychlinsky
May 1, 2012·Developmental Cell·Philippe V AfonsoCarole A Parent
Sep 8, 2012·American Journal of Respiratory and Critical Care Medicine·Luman WangRui He
Feb 26, 2013·Nature Reviews. Immunology·Elzbieta Kolaczkowska, Paul Kubes
Jan 15, 2015·The Journal of Experimental Medicine·Yingying DongWen Ning
Jan 13, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jiaoyan LvRui He
May 10, 2018·The New England Journal of Medicine·David J Lederer, Fernando J Martinez

❮ Previous
Next ❯

Citations

Mar 16, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jian ZhouJinhan He
May 19, 2021·European Journal of Pharmacology·Hayder M Al-KuraishyGaber El-Saber Batiha
Jul 1, 2021·Expert Opinion on Drug Discovery·Till A RöhnGebhard Thoma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here